$IDXG On The Run Again and this time it will be sustained

Let's recap CC:

1. New York State and AETNA approvals of ThyraMIR®, microRNA assay

2. Talked about the Debt being restructured

3. No more offerings

4. Reduced operating costs

5. Talks of doing business with their BarreGen model

6. Talks of partnering with another bio he didn't discuss.

7. EPS value of $3.25 vs -($12.04) same quarter last year

8. Sales of $3.122 million.

9. Goldman, Rodman and Renshaw, Barclays were on the CC too big boys will be here soon enough count on it.

10. 64% of the S/S is SHORT

11. Raised $14 million in gross equity and restructured over $9.3 million of secured debt

12. Revenue increased 39%

Also most importantly the Patent Approval!!!

European Patent Decision data.epo.org/publication-server/pdf-document?pn=2772550&ki=B1&cc=EP

ALSO FULL YEAR HIGHLIGHTS READ HERE: ih.advfn.com/p.php?pid=nmona&article=74215692

註釋

Alerted this on Twitter earlier in the day. Will post charts in real time next time.